The 10058-F4, which prevents the interaction of MYC with MAX, used in several preclinical studies, was able to reduce BCR-ABL kinase activity and CIP2A expression in CML patients [121]. Here, MYC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.